FDA Approves Emcitate (Tiratricol) — First-Ever Treatment for MCT8 Deficiency (Allan-Herndon-Dudley Syndrome)

FDA Approves Emcitate (Tiratricol) — First-Ever Treatment for MCT8 Deficiency (Allan-Herndon-Dudley Syndrome)

September 28, 2026. Egetis Therapeutics (Nasdaq Stockholm: EGTX) announced that the FDA approved EMCITATE (tiratricol), a thyroid hormone receptor agonist, "for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley syndrome)" — the first FDA-approved treatment option for patients with MCT8 deficiency in the United States.

The disease: MCT8 deficiency is a rare, life-limiting, X-linked disorder caused by pathogenic mutations in the SLC16A2 gene, which impair the cell-surface transporter that moves thyroid hormone into the brain. The result is severe neurodevelopmental impairment plus chronic peripheral T3 excess (a hypermetabolic state straining heart, muscle, liver, and kidneys). Reported median life expectancy is approximately 35 years. There was previously no approved treatment anywhere that addressed the peripheral thyrotoxicosis driving the morbidity.

Key details from the announcement:

• Evidence base: the ReTRIACt trial, Triac Trial I, Triac Trial II, the Erasmus MC Cohort Study, the EMC Survival Study, and the US Expanded Access Program.
• The FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval — a transferable asset worth potentially hundreds of millions of dollars.
• Label limits: not recommended for primary hypothyroidism; boxed warning that it is not for obesity or weight loss (tiratricol's history as a weight-loss agent drove this).
• Access: Egetis launched the Egetis RareLink patient support program with specialty pharmacy PANTHERx Rare.
• CEO Nicklas Westerholm: "Today marks a turning point for patients living with MCT8 deficiency and their caregivers, who have waited long for an approved treatment in the United States."

What it means: This continues 2026's run of first-ever disease approvals (Sanfilippo A, ataxia-telangiectasia, FOP, Alexander disease)¹ and adds a rare pediatric disease PRV to the market. The boxed warning reflects the FDA's memory of tiratricol's misuse as a diet drug decades ago — the indication here is narrow and metabolic, not weight loss.